Our Tests


Also known as: inv(3) FISH, RPN1-EVI1 FISH

« Back to test list


Rearrangements of chromosome 3 which result in fusion of the RPN1 and EVI1 (also known as MECOM) genes are found in a small number of patients with acute myeloid leukaemia (AML), or with therapy-related AML or myelodysplastic syndrome (MDS). These patients often have thrombocytosis. This gene fusion defines a specific AML subtype, and it carries prognostic implications.

Clinical Utility

Fusion of RPN1 and EVI1 is associated with poor prognosis.

This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.

Test Method

Fluorescent in situ hybridisation (FISH) analysis, using probes designed to detect RPN1-EVI1 gene fusion.

Test Ordering

This test is usually requested by a haematologist or oncologist.

0.5 mL bone marrow in transport media (or 10 mL blood in lithium heparin if blasts>10%).

To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.

We also recommend that the patient or another adult check the labelling of request forms and sample tubes.



This test may have a rebate for all or part of the cost.

Medicare Rebate

This test has a Medicare rebate of $196.35, subject to the requirements of the Medicare descriptor being met. The MBS item number is 73314.

Turnaround Time

2 working days.